

ANIKA THERAPEUTICS INC
Form 8-K
December 24, 2003

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

December 22, 2003

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Massachusetts

(State or Other Jurisdiction of
Incorporation)

000-21326

(Commission File
Number)

04-3145961

(I.R.S. Employer Identification No.)

160 New Boston Street, Woburn, Massachusetts

(Address of Principal Executive Offices)

01801

(Zip Code)

Registrant's Telephone Number, Including Area Code: **(781) 932-6616**

Item 5: Other Events and Required FD Disclosure.

On December 22, 2003, Anika Therapeutics, Inc. issued a press release (Press Release) announcing the signing of an exclusive, multi-year U.S. licensing and supply agreement with Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, for Anika s ORTHOVISC® osteoarthritis product. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference in its entirety.

Item 7: Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits

Exhibit No.	Description
99.1	Press Release issued by Anika Therapeutics, Inc. on December 22, 2003

SIGNATURES

Edgar Filing: ANIKA THERAPEUTICS INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Anika Therapeutics, Inc.

December 24, 2003

By: /s/ William J. Knight
William J. Knight
Chief Financial Officer

3

Exhibit Index

Exhibit No.	Description
99.1	Press Release of Anika Therapeutics, Inc. dated December 22, 2003